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ABSTRACT
Background: Alcohol consumption is a frequently studied risk factor for chronic diseases, but many studies are
hampered by self-report of alcohol consumption. The urinary metabolite ethyl glucuronide (EtG), reflecting alcohol
consumption during the past 72 h, is a promising objective marker, but population data are lacking.
Objective: The objective of this study was to assess the reliability of EtG as a marker for habitual alcohol consumption
compared with self-report and other biomarkers in the general population.
Methods: Among 6211 participants in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort,
EtG concentrations were measured in 24-h urine samples. EtG was considered positive when concentrations were
≥100 ng/mL. Habitual alcohol consumption was self-reported by questionnaire (categories: no/almost never, 1–4 units
per month, 2–7 units per week, 1–3 units per day or ≥4 units per day). Plasma HDL cholesterol concentration,
erythrocyte mean corpuscular volume (MCV), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
γ -glutamyltransferase (GGT) were determined as indirect biomarkers of alcohol consumption. Sensitivity, specificity,
positive and negative predictive value, and proportions of agreement between reported consumption and EtG were
calculated. To test the agreement of EtG concentration and alcohol consumption in categories, linear regression analysis
was performed. In addition, the association between EtG concentrations and indirect biomarkers was analyzed.
Results: Mean age was 53.7 y, and 52.9% of participants men. Of the self-reported abstainers, 92.3% had an EtG
concentration <100 ng/mL. Sensitivity was 66.3%, positive predictive value was 96.3%, and negative predictive value
was 47.4%. The proportion of positive agreement was 78.5%, and the proportion of negative agreement was 62.7%.
EtG concentrations were linearly associated with higher categories of alcohol consumption (P-trend < 0.001), adjusted
for age, sex, and renal function. EtG was positively related to MCV, HDL cholesterol, and GGT but not to AST and ALT
concentrations.
Conclusions: This study shows that urinary EtG is in reasonable agreement with self-reported alcohol consumption
and therefore can be used as an objective marker of habitual alcohol consumption in the general population. J Nutr
2019;149:2199–2205.
Keywords: ethyl glucuronide, habitual alcohol consumption, self-report, biomarker, general population
Introduction
Alcohol consumption is frequently studied as a risk factor for
chronic diseases (1–3). The vast majority of these studies are
observational and rely on self-reported alcohol consumption.
Self-report has proven to be a relatively unreliable source
of information, often leading to underreporting of alcohol
consumption (4). There obviously is a need for objective
markers of alcohol consumption that can be easily assessed.
The determination of ethanol in blood, exhaled breath, or
urine has a very limited detection window and only expresses
alcohol consumption during the past few hours (5). Indirect
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biomarkers, such as liver enzymes, are usually markers of
chronic excessive alcohol consumption (6). These markers do
not directly represent metabolites of alcohol but merely express
the influence of alcohol on various organs. Also, other factors
are known to influence these markers, including nonalcoholic
liver diseases, which cause a rise in liver enzymes (7). In general,
indirect biomarkers are not specific enough to be suitable
markers for habitual alcohol consumption.
During the past several decades, new markers of alcohol
consumption have been identified (7, 8). A promising marker
is the urinary metabolite ethyl glucuronide (EtG), a direct
marker of alcohol consumption. It is the small part (<0.1%)
of ethanol that is not oxidized by the liver but is excreted
in urine as EtG after conjugation with glucuronic acid.
After complete elimination of ethanol, EtG has a half-life of
2–3 h (9). Therefore, EtG is detectable in urine for a longer
time period than ethanol, with a window of detection of
∼72 h (10). Many studies have used EtG as a marker in
abstention programs in alcohol-dependent persons (11–16). In
these often controlled studies, EtG has been validated as a
reliable marker to detect short-term alcohol consumption. Less
frequently, EtG has been studied as a potential marker for
habitual alcohol consumption in the general population. To
date, 1 study has assessed the value of EtG as a potential marker
of habitual, nonabusive alcohol consumption in a population-
based study (17) by comparing urinary EtG concentrations in
175 male workers to other known alcohol markers. This study
showed that higher urinary EtG concentrations were associated
with higher concentrations of other biochemical markers of
alcohol consumption. The relation between urinary EtG and
self-reported alcohol consumption remains to be investigated.
In the current study, we investigated the association between
self-reported alcohol consumption and EtG as a marker of
habitual alcohol consumption in a large general population-
based cohort. Furthermore, we compared EtG concentrations
with other known biomarkers of alcohol consumption to




The Prevention of Renal and Vascular End-Stage Disease (PREVEND)
cohort is a Dutch longitudinal cohort drawn from the general
population in the city of Groningen in 1997, originally established to
monitor the long-term development of cardiovascular and renal diseases
in participants with microalbuminuria. Details of this study have been
published elsewhere (18). In summary, all inhabitants aged 28–75 y
(n = 85,421) were asked to provide a morning urine sample and to
complete a short questionnaire. In total, 40,856 (47.8%) participants
responded. Subjects with a urinary albumin concentration >10 mg/L
were invited for further participation. After exclusion of pregnant
This work was supported by the EU Joint Programming Initiative “A Healthy Diet
for a Healthy Life” on Biomarkers BioNH FOODBALL(grant 529051002), The
Food Biomarkers Alliance. IATvdL and SvO were partly funded by the National
Institutes of Health (grant U10 AA025286).
Author disclosures: IATvdL, JWJB, ICS, LMK, DJT, AJvB, SvO, DEG, and SJLB,
no conflicts of interest.
Address correspondence to IATvdL (e-mail: I.A.T.vandeLuitgaarden@umcutrech
t.nl).
Abbreviations used: ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; eGFR, estimated glomerular filtration rate; EtG, ethyl glucuronide; FN,
false negative; FP, false positive; GGT, γ -glutamyltransferase; MCV, erythrocyte
mean corpuscular volume; PREVEND, Prevention of Renal and Vascular End-
Stage Disease; TN, true negative; TP, true positive.
women and participants using insulin, 6000 participants with a urinary
albumin concentration >10 mg/L were included. In addition, a random
sample of 2592 participants without microalbuminuria was included.
The total number of participants was 8592. The PREVEND study was
conducted in accordance with the Declaration of Helsinki guidelines
and was approved by the Medical Ethics committee of the University
Medical Center Groningen. All participants gave written informed
consent. During the study period (1997–2013), participants attended
5 subsequent screening rounds.
In the current study, we included participants who attended the
second screening round (n = 6894), which lasted from April 2001 until
December 2003, because urinary EtG concentrations were measured
in urine samples that were collected during this period. We excluded
participants without EtG measurements (n = 60) or for whom
data on self-reported alcohol consumption were missing (n = 64).
Moreover, we excluded participants when urinary analysis (urinary
leukocyte measurements done byNephur-test+ leuco sticks; Boehringer
Mannheim) showed evidence of a urinary tract infection, defined as
a test result >“2+ leukocytes” (n = 363) or >“3+ erythrocytes”
(n = 196). Previous research has shown that bacterial contamination
can influence EtG concentrations, which can lead to both false-positive
and false-negative results (8, 19). The analytic sample included 6211
participants.
Biomarkers of alcohol consumption
Ethyl glucuronide.
Participants were asked to collect two 24-h urine samples maximal
4 d before the second visit after thorough oral and written instruction.
In this instruction, the participants were asked to avoid heavy exercise
as much as possible during the urine collection and to postpone the
urine collection in case of urinary tract infection, menstruation, or fever.
Participants stored the samples temporarily at home at a temperature
of 4◦C prior to the visit. After handing in, aliquots of these urine
specimens were stored at –20◦C. EtG concentrations were measured
in the second 24-h urine sample using the Thermo Scientific DRI EtG
assay, which is commonly used as a screening test for EtG. It has a
detection limit of 100 ng/mL. Previously, this assay has shown overall
good agreement (r2 = 0.931) with established LC-MS methods in
detecting EtG. Moreover, agreement was shown to be equally good
(r2 = 0.961) specifically for low concentrations of EtG in a subset of
urine samples with EtG concentrations ranging from 100 to 5000 ng/mL
(20). Intra- and interassay coefficients of variation were previously
established at <1.7% and <2.2%, respectively (20). In accordance
with previous research (21–23), a cutoff value of ≥100 ng/mL was
defined for the assessment of alcohol consumption, indicating that
EtG concentrations above this threshold were regarded as positive for
intentional alcohol consumption. This cutoff value is highly sensitive.
Controlled experiments have shown that EtG was already detectable
after consumption of very small ethanol doses (≤10 g) (24). Moreover,
there are examples of unintentional alcohol “consumption” (e.g.,
alcohol in ethanol-based mouthwash) that could lead to low but
detectable EtG concentrations in urine (25). To exclude these false-
positive samples due to unintentional alcohol consumption,we included
a sensitivity analysis in which we used a cutoff value of 500 ng/mL,
which is also frequently used in the assessment of intentional alcohol
consumption (14–16). We defined potential inadequate 24-h urine
collections (i.e., over- or undercollection) as the upper and lower 2.5%
of the difference between the estimated and measured volume of a
subject’s 24-h urine sample. The estimated 24-h urine volume was
derived from the following formula: creatinine clearance = [(urine
creatinine × 24-h urine volume)/(serum creatinine)], where creatinine
clearance was estimated using the Cockcroft–Gault formula.
Other biomarkers.
Plasma HDL cholesterol, erythrocyte mean corpuscular volume (MCV),
and the liver enzymes aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and γ -glutamyltransferase (GGT) were deter-
mined as indirect biomarkers of alcohol consumption using standard
laboratory methods. Plasma AST, ALT, and GGT were measured by
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a standardized enzymatic method (Cobas c501; Roche Diagnostics).
Serum HDL cholesterol was measured by a homogeneous method
(direct HDL-C, Aeroset System; Abbott Laboratories), and MCV
concentrations were measured using a Coulter Counter STKS sum
(Coulter Corporation).
Self-reported alcohol consumption
Participants were asked to complete a questionnaire regarding demo-
graphics, cardiovascular and renal history, drug use, alcohol consump-
tion, and smoking. Participants were asked about the frequency of their
habitual alcohol consumption with the following answer categories: 1)
no, almost never; 2) 1–4 units/mo, 3) 2–7 units/wk, 4) 1–3 units/d, or
5) ≥4 units/d. In the Netherlands, a standard serving of an alcoholic
beverage contains ∼10 g of alcohol. Alcohol consumption was defined
according to the 5 categories of the questionnaire: abstention, light,
light–moderate, moderate, and heavy alcohol consumption.
Other covariates
Information about age, sex, height, weight, educational level, and
smoking was obtained from the questionnaire. Educational level was
classified into the categories low (primary education or intermediate
vocational education), middle (higher secondary education), and high
(higher vocational education and university). Smoking status was
categorized into nonsmoking, 1–10 cigarettes/d, 11–20 cigarettes/d,
or >20 cigarettes/d. Estimated glomerular filtration rate (eGFR) was
calculated using the combined creatinine cystatin C-based Chronic
Kidney Disease Epidemiology Collaboration equation (26).
Statistical analysis
All statistical analyses were performed using IBM SPSS 24.0 for
Windows. We used descriptive statistics to assess the distribution of
the data. Missing values were present for eGFR (n = 322, 5%), HDL
cholesterol (n = 227, 3.7%), MCV (n = 44, 0.7%), AST (n = 220,
3.5%), ALT (n= 220, 3.5%), and GGT (n= 220, 3.5%) concentrations
and replaced by the mean (mean eGFR = 92.27 mL/min/1.73 m2,
mean HDL cholesterol = 48.18 mg/dL, and mean MCV = 90.51 fL,
respectively) or the median (median AST = 23 U/L, median ALAT = 17
U/L, and median GGT = 24.0 U/L, respectively).
We tabulated demographic and laboratory data stratified by the
5 alcohol consumption categories.We conducted the Pearson chi-square
test to assess the correlation between EtG concentration and self-
reported alcohol consumption. A contingency table was constructed,
with EtG concentrations categorized into negative (<100 ng/mL) or
positive (≥100 ng/mL) for alcohol consumption. Self-reported alcohol
consumption was categorized as “no alcohol consumption” or “al-
cohol consumption.” Alcohol consumption was further stratified into
4 categories. We calculated sensitivity [the number of true EtG positives
(TPs) divided by the sum of TPs and false negatives (FNs)], specificity
[the number of true EtG negatives (TNs) divided by the sum of TNs and
false positives (FPs)], positive predictive value (TPs divided by the sum
of TPs and FPs) and negative predictive value (TNs divided by the sum
of TNs and FNs) of the EtG test for self-reported alcohol consumption
categories.
For both self-report and urinary EtG, no established gold standards
are available; therefore, the proportion of observed agreement was
calculated. Agreement is an absolute measure because it quantifies
the proportion of cases for which the 2 methods agree (27). In
this analysis, agreement is the probability that a participant with
a certain self-reported alcohol consumption has a corresponding
urinary EtG concentration above or below cutoff. The proportion of
specific agreement expresses the agreement separately for positive and
negative ratings. In this case, the proportion of positive agreement is
the proportion of participants who reported to be habitual alcohol
consumers (i.e., who selected 1 of the 4 alcohol consumption categories)
and have an EtG concentration ≥100 ng/mL. Subsequently, the
proportion of negative agreement reflects the proportion of participants
reporting abstention who have a corresponding EtG concentration
<100 ng/mL. Calculations of these proportions were based on the
methods proposed by de Vet et al. (27). As a secondary analysis, all
analyses were also performed using an EtG cutoff value of 500 ng/mL.
To test the continuous association between alcohol consumption
categories and EtG concentration, we performed a multiple linear
TABLE 1 Baseline characteristics of 6211 PREVEND participants1
Alcohol consumption category (by self-report) EtG concentration
No, almost never 1–4 units/mo 2–7 units/wk 1–3 units/d ≥4 units/d <100 ng/mL ≥100 ng/mL
Total participants, n (%) 1539 (24.8) 1054 (17.0) 1969 (31.7) 1381 (22.2) 268 (4.3) 2997 (48.3) 3214 (51.7)
Men, n (%) 599 (38.9) 487 (46.2) 1111 (56.4) 871 (63.1) 215 (52.9) 1389 (46.3) 1894 (58.9)
Women, n (%) 940 (61.1) 567 (53.8) 858 (43.6) 510 (36.9) 53 (47.1) 1608 (53.7) 1320 (41.1)
Age, y 55.7 ± 12.6 53.9 ± 13.0 51.5 ± 11.6 54.1 ± 11.0 54.6 ± 9.9 54.3 ± 12.7 53.1 ± 11.4
BMI, kg/m2 26.9 [6.0] 26.3 [5.5] 25.9 [5.1] 25.7 [4.8] 26.3 [5.5] 26.7 [5.6] 25.7 [5.1]
eGFR, mL/(min · 1.73 m2) 88.6 ± 18.3 91.1 ± 16.7 94.5 ± 15.7 93.7 ± 15.4 93.9 ± 15.0 90.5 ± 17.3 94.0 ± 15.7
Smoking, n (%)
No smoking 551 (35.8) 379 (36.0) 579 (29.4) 250 (18.1) 29 (10.8) 1027 (34.3) 761 (23.7)
1–10 cigarettes/d 441 (28.7) 366 (34.7) 631 (32.0) 421 (30.5) 45 (16.8) 903 (30.1) 1001 (31.1)
11–20 cigarettes/d 396 (25.7) 246 (23.3) 573 (29.1) 502 (36.4) 109 (40.7) 790 (26.4) 1036 (32.2)
>20 cigarettes/d 151 (9.8) 63 (6.0) 186 (9.4) 208 (15.1) 85 (31.7) 277 (9.2) 416 (12.9)
Educational level, n (%)
Low 942 (61.2) 479 (45.4) 684 (34.7) 478 (34.6) 112 (41.8) 1554 (51.9) 1141 (35.5)
Middle 379 (24.6) 288 (27.3) 534 (27.1) 332 (24.0) 65 (24.3) 760 (25.4) 838 (26.1)
High 218 (14.2) 287 (27.2) 751 (38.1) 571 (41.3) 91 (34.0) 683 (22.8) 1235 (38.4)
Plasma analytes
HDL-C, mg/dL 46.3 ± 10.9 47.3 ± 10.7 48.3 ± 11.5 50.2 ± 12.3 50.7 ± 13.2 46.6 ± 10.8 49.7 ± 12.1
MCV, fL 89.4 ± 4.7 89.6 ± 4.5 90.5 ± 4.2 91.7 ± 4.4 94.0 ± 4.7 89.7 ± 4.6 91.3 ± 4.5
AST, U/L 22.0 [7.0] 22.0 [6.0] 23.0 [7.0] 23.0 [7.0] 25.0 [8.0] 22.0 [7.0] 23.0 [7.0]
ALT, U/L 17.0 [11.0] 17.0 [10.0] 17.0 [11.0] 18.0 [11.0] 20.0 [14.5] 17.0 [11.0] 17.0 [12.0]
GGT, U/L 24.0 [18.0] 22.0 [18.0] 24.0 [21.0] 27.0 [25.0] 37.5 [46.8] 24.0 [19.0] 25.0 [24.0]
1Values are n (%), means ± SDs, or medians [IQRs]. Educational level: low, primary education or intermediate vocational education; middle, higher secondary education; and high,
higher vocational education and university. ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; EtG, ethyl glucuronide;
GGT, γ -glutamyltransferase; HDL-C, HDL cholesterol; MCV, mean corpuscular volume; PREVEND, Prevention of Renal and Vascular End-Stage Disease.
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regression analysis. Because of the skewed distribution, the natural
logarithm of EtG concentration was used as continuous outcome.
We included only participants with detectable EtG concentrations
(i.e., concentrations ≥100 ng/mL) in this analysis (n = 3219). The
“abstention” alcohol category was used as reference. First, a crude
analysis (model 1) was conducted. Age, sex, and eGFR are potential
effect modifiers for EtG concentrations (21–23). Therefore, these
variables and their interaction terms with alcohol consumption were
separately entered in the model to test for influence on the relation
between EtG concentration and alcohol consumption (model 2). Age
was added as a continuous variable, whereas eGFR was added
as a categorical variable, defined as either impaired renal function
[eGFR <90 mL/(min · 1.73 m2)] or normal renal function [eGFR
≥90mL/(min · 1.73m2)]. In case significant interaction terms (P< 0.10)
in our minimally adjusted model were found, analyses were stratified
accordingly. Data of these linear regression analyses are presented as
geometric means. To study the association between indirect biomarkers
and EtG concentrations, we performed a second regression analysis.
Data of this analysis are presented as back-transformed coefficients
that indicate the increase in EtG concentration per 1 unit increase
in biomarker concentration. As a sensitivity analysis, we reanalyzed
the data excluding subjects with potential inadequate 24-h urine
collections. Furthermore, we repeated the regression analyses excluding




Among 6211 PREVEND participants, the mean age was
53.7 y (SD = 12.0), and 52.9% were men. Of the participants,
75.2% consumed alcohol according to self-report (Table 1).
Women reported lower alcohol consumption compared with
men and were more often abstainers (32% compared with
18%, respectively).Moderate to heavy drinkers weremore often
current smokers: 64% of the participants in the abstention
group smoked at least 1 cigarette a day compared with 82%
in the moderate alcohol consumption group and 89% in the
heavy alcohol consumption group.
Detection of EtG
In 51.7% of the study population, EtG concentrations were
above detection limit (≥100 ng/mL), indicating intentional
alcohol consumption. Cross-tabulations (Table 2) between self-
reported alcohol consumption and EtG concentration indicate
that 92.3% (95% CI: 91.6%, 93.0%) of the participants
with self-reported abstention had an EtG concentration
<100 ng/mL. On the other hand, 33.7% (95% CI: 33.1%,
34.3%) of the participants with self-reported alcohol con-
sumption had a discordant EtG concentration below cutoff
value. Sensitivity for EtG as a marker is 66.3% (95% CI:
65.1%, 67.5%). When stratified for alcohol consumption
category, sensitivity became higher for higher alcohol con-
sumption: 30.3% (95% CI: 29.2%, 31.4%) in category 1–
4 units/mo, 64.2% (95% CI: 63.0%, 65.4%) in category 2–
7 units/wk, 91.5% (95% CI: 90.8%, 92.2%) in category 1–
3 units/d, and 92.5% (95% CI: 91.8%, 93.2%) in category
≥4 units/d. The positive predictive value was 96.3%, and the
negative predictive value was 47.4%.
Measure of agreement
Proportion of positive agreement, referring to the proportion
of participants indicating alcohol consumption on self-report
that also had an EtG concentration ≥100 ng/mL, was 78.5%
(95% CI: 77.4%, 79.5%). Proportion of negative agreement,
reflecting the proportion of participants reporting abstention
with a corresponding EtG concentration <100 ng/mL, was
62.7% (95% CI: 61.5%, 63.9%). In the multiple linear
regression, the interaction term for eGFR was statistically
significant (P = 0.01). Therefore, we also calculated agree-
ment stratified for eGFR. Proportion of positive agreement
was lower, whereas proportion of negative agreement was
higher, in participants with an impaired renal function
[eGFR <90 mL/(min · 1.73 m2)] compared with participants
with a normal renal function [eGFR ≥90 mL/(min · 1.73 m2)]
(Table 3).
Sensitivity analyses
When a higher cutoff value for EtG was used (i.e., 500 ng/mL),
the diagnostic measures were consistently lower (Table 3),
except for specificity and positive predictive value. Exclusion of
subjects with potential inadequate 24-h urine collection did not
alter any of the results (data not shown).
Association between self-reported alcohol
consumption and EtG concentrations
EtG concentrations were directly associated with categories
of increasing alcohol consumption (P < 0.001) (Table 4).
Because the interaction term for eGFR showed a significant
interaction (P-interaction = 0.01), the regression analyses were
also stratified for eGFR [eGFR <90 mL/(min · 1.73 m2) and
eGFR ≥90 mL/(min · 1.73 m2)]. However, stratified analyses
did not show different results for renal function categories.
Exclusion of participants with missing data for eGFR (n = 169)
did not alter the results (data not shown).
TABLE 2 Cross-tabulation between self-reported alcohol consumption and urinary EtG
concentration among 6211 PREVEND participants using a cutoff value of 100 ng/mL1
Interpretation of EtG concentration
Positive (≥100 ng/mL) Negative (<100 ng/mL) Total
Self-reported alcohol consumption, n (%)
No 118 (7.7) 1421 (92.3) 1539
Yes 3096 (66.3) 1576 (33.7) 4672
Stratified by alcohol consumption category, n (%)
1–4 units/mo 319 (30.3) 735 (69.7) 1054
2–7 units/wk 1265 (64.2) 704 (35.8) 1969
1–3 units/d 1264 (91.5) 117 (8.5) 1381
≥4 units/d 248 (92.5) 20 (7.5) 268
Total, n (%) 3214 (51.7) 2997 (48.3) 6211
1EtG, ethyl glucuronide; PREVEND, Prevention of Renal and Vascular End-Stage Disease.
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Total (n = 6211)
Sensitivity 66.3 57.1
Specificity 92.3 96.0
Positive predictive value 96.3 97.8
Negative predictive value 47.4 42.5
Proportion positive agreement 78.5 72.1
Proportion negative agreement 62.7 58.9
Impaired renal function [eGFR <90 mL/(min · 1.73 m2)] (n = 2425)
Proportion positive agreement 75.6 68.7
Proportion negative agreement 66.4 63.1
Normal renal function [eGFR ≥90 mL/(min · 1.73 m2)] (n = 3786)
Proportion positive agreement 80.1 74.0
Proportion negative agreement 59.6 55.5
1Comparison of diagnostic measures for different cutoff values of EtG concentrations. Sensitivity: TP/(TP + FN); specificity:
TN/(TN + FP); positive predictive value: TP/(TP + FP); negative predictive value: TN/(TN + FN). eGFR, estimated glomerular filtration
rate; EtG, ethyl glucuronide; FN, false EtG negatives; FP, false EtG positives; PREVEND, Prevention of Renal and Vascular End-Stage
Disease; TN, true EtG negatives; TP, true EtG positives.
Association between indirect biomarkers and EtG
concentrations
Linear regression analyses showed a significant positive as-
sociation between HDL cholesterol (unstandardized β: 1.01
ng/mL; 95% CI: 1.01, 1.02 ng/mL), MCV (β: 1.10 ng/mL;
95% CI: 1.08, 1.11 ng/mL), and GGT biomarkers (β: 1.01
ng/mL; 95% CI: 1.00, 1.01 ng/mL) and EtG concentrations.
Plasma AST (β: 1.00 ng/mL; 95% CI: 0.99, 1.01 ng/mL) and
ALT (β: 1.00 ng/mL; 95% CI: 0.99, 1.01 ng/mL) were not
significantly associated with EtG concentrations. Adjustment
for age, sex, and eGFR did not alter these results, neither did
exclusion of participants withmissing values (n= 219) (data not
shown).
Discussion
In this study, we showed that EtG is in reasonable agreement
with self-report when assessing habitual alcohol consumption.
The positive predictive value was 96%, the negative predictive
value was 48%, and specificity was high (92%). By contrast,
overall sensitivity was only 66.3%, which increased in the
moderate to heavy drinking categories (91–93%). Furthermore,
the proportions of positive and negative agreement were 78.5%
and 62.7%, respectively, both reflecting a reasonable agreement
between urinary EtG and self-reported alcohol consumption.
Categories of increasing alcohol consumption were linearly
associated with EtG concentrations. Moreover, some, but not
all, indirect biomarkers of alcohol consumption were linearly
associated with EtG concentrations.
Strengths and limitations
Our study is the first to compare urinary EtG concentrations
to self-reported habitual alcohol consumption and other
biomarkers in a large cohort. Until now, measurements of
urinary EtG concentrations on such a large scale have not
been performed in epidemiologic research. Because of the large
sample size, we were able to calculate precise estimates of
sensitivity, specificity, and positive and negative predictive value
of urinary EtG as a diagnostic test. Moreover, our study is
the first to compare urinary EtG concentrations with both
self-reported consumption and other biomarkers of alcohol
consumption. However, our study has some limitations.
It is important to acknowledge that no gold standard
for habitual alcohol consumption is available. We used self-
reported consumption to estimate the predictive value of EtG as
a biomarker. Therefore, measurement error in self-report could
have affected the estimated accuracy of EtG.
Furthermore, we based our self-reported alcohol consump-
tion data on a questionnaire that provided only limited
information. Habitual alcohol consumption was divided into
TABLE 4 Associations between alcohol consumption categories and EtG concentrations in PREVEND participants with detectable
EtG concentrations (n = 3219)1
Alcohol consumption category
Abstention (reference)







Model 12 620 (470, 820) 1068 (583, 1955) 2343 (1326, 4138) 5497 (3109, 9711) 15,139 (8168, 28,057) <0.001
Model 23 670 (409, 1097) 1064 (467, 2426) 2109 (935, 4755) 4346 (1850, 10,209) 10,467 (4081, 26,849) <0.001
1All values are geometric means (95% CIs) of linear regression analyses and were found to be statistically significant, P < 0.001. eGFR, estimated glomerular filtration rate; EtG,
ethyl glucuronide; PREVEND, Prevention of Renal and Vascular End-Stage Disease.
2Crude analysis.
3Adjusted for age (y), sex, and eGFR [mL/(min · 1.73 m2)].
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5 categories, and the time since last alcohol consumption
was not recorded. Therefore, only the global distinction
between abstinent, light, light–moderate, moderate, and heavy
drinkers could be made. It was not possible to relate EtG
concentrations with fixed amounts of alcohol; therefore, it
remains unclear whether the concentrations of EtG can
reflect certain amounts of alcohol at an individual level.
Nevertheless, we have shown that on a group level, EtG
concentrations increase with increasing alcohol consumption
categories. Therefore, the results from our study can be used
to draw conclusions on a group level but not on an individual
level.
Another limitation is the use of the natural logarithm of EtG
concentration as a dependent variable in the multiple linear
regression analysis. Using a log-transformed variable leads to
the loss of cases for which the EtG concentration was below
the detection limit and therefore to an overestimation of EtG
concentrations in the “abstention” category. The majority of
the cases in the abstention category in this analysis will consist
of false positives, leading to an underestimation of the true
differences between consumption categories.
Explanation of results
In our study, we found that sensitivity was low compared
with that of previous studies, in which sensitivity ranged from
79% to 100% (11–16). This is probably because we studied
habitual alcohol consumption, which ranges from abstention
to more than 4 units per day. EtG is only detectable up to
72 h after alcohol consumption. Consequently, a substantial
part of the group of light alcohol consumers (1–4 units/mo)
will have an EtG concentration below the cutoff value, leading
to misclassification of these consumers. The categories in
which participants drank at least 1 alcoholic consumption per
day (the moderate and heavy consumption categories) had
a higher sensitivity (91–93%). Repeated sampling of urine
on different days, also taking into account the differences in
alcohol consumption patterns during weekdays and weekends,
would reduce the misclassification of light drinkers because
this increases the chance of detecting EtG in the people who
consume alcohol only occasionally. For convenience, EtG can
be measured in spot urine samples if corrected for urinary
creatinine concentration to compensate for urine dilution (28).
Repeated urine sampling, however, might be a less feasible
option in large-scale population research.
The reasonable proportions of agreement between EtG and
self-reported alcohol consumption do not entirely reflect the
concerns of underreporting of alcohol consumption as raised
in previous research, in which urinary EtG concentrations
were compared to self-reported alcohol consumption in more
controlled settings. In these studies, discordance between EtG
and self-reported abstention was up to 40% (16). In our study,
only 8% of the participants who reported abstention had
positive EtG concentrations. The discrepancy can probably be
explained by differences in study population and study design:
These studies used a population of alcohol-dependent persons
in an abstention program, whereas our study population was a
sample of the general population, in which the focus was not
on alcohol consumption. Compared to the general population,
alcohol-dependent persons in an abstention program are
probably more likely to underreport alcohol consumption
because this might have consequences for their participation in
the program. Furthermore, urine testing will probably be carried
out at a time when the chance of catching unallowed alcohol
consumption is highest.
Proportions of agreement differed when stratified by eGFR.
Participants with impaired renal function had higher propor-
tions of negative agreement and lower proportions of positive
agreement. This can potentially be explained by the fact that
proportion of agreement is related to prevalence of, in this case,
alcohol consumption (27). People with impaired renal function
are more often abstainers compared with people with a normal
renal function, probably because of health-related issues.
We found an association between urinary EtG and the
indirect biomarkers HDL cholesterol, MCV, and GGT but
not with AST and ALT. These findings are in line with
the results of Kilo et al. (17), who also examined habitual
alcohol consumption. This consistently demonstrates that some,
but not all, indirect biomarkers are associated with EtG
concentrations in a general population with a wide range of
alcohol consumption—from abstainers to heavy drinkers.
The utility of the application of EtG as a biomarker
for alcohol consumption is highly dependent on the cutoff
value used. Cutoff values most often used are 100, 200, and
500 ng/mL. Previous studies have commented on the limitations
of each cutoff value (11, 22). In the current study, the motivation
to choose 100 ng/mL as a cutoff value was largely based on
previous studies that posed a research question similar to ours
(13, 21, 22). McDonell et al. (13) calculated the sensitivity and
specificity for cutoff values of 100, 200, and 500 ng/mL in light
and heavy drinking in alcohol-dependent patients following
an abstention program. They concluded that a cutoff value of
100 ng/mL was likely to detect both light and heavy drinkers,
whereas a cutoff value of 500 ng/mL could only detect the heavy
drinkers during the previous day. Using a low cutoff value can
lead to more false-positive cases. A cutoff value of 500 ng/mL
would exclude all false-positive cases, but it would lead to lower
sensitivity, especially in light to moderate drinkers.
The choice of the “right” cutoff value remains subject to
debate. However, when applying a cutoff value of 500 ng/mL
in our study, similar conclusions can be drawn. Specificity and
positive predictive value increase at the cost of a decrease in
sensitivity, most pronounced in the lower alcohol consumption
categories.
In conclusion, this study shows that urinary EtG can be
used as a measure of habitual alcohol consumption on a
group level in epidemiologic research. The advantage of using
an objective biomarker instead of a subjective approach for
alcohol consumption is that it is not hampered by recall error
or misclassification. Future studies should include the use of
urinary EtG in the assessment of alcohol as a risk factor for
chronic diseases in population research.
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